Patient characteristics
Characteristic . | No. (%)* . |
|---|---|
| Median age, y (range) | 47 (19-64) |
| Sex | |
| Male | 14 (67) |
| Female | 7 (33) |
| Stem cell source | |
| PBSC | 11 (52) |
| BM | 10 (48) |
| Donor source | |
| HLA-matched, related | 11 (52) |
| HLA-mismatched, related | 2 (10) |
| HLA-matched, unrelated | 8 (38) |
| Diagnosis | |
| MDS/AML | 6 (29) |
| CML/myelofibrosis | 4 (19) |
| Non-Hodgkin lymphoma | 6 (29) |
| ALL/CLL | 4 (19) |
| Myeloma | 1 (4) |
| Acute GVHD grade | |
| 1 | 3 (14) |
| 2 | 14 (67) |
| 3-4 | 4 (19) |
| Organ involvement, n (%) | |
| Skin | 9 (43) |
| GI tract | 12 (57) |
| Liver | 3 (14) |
| Median no. infliximab doses (range) | 4 (2-9) |
| Median time to infliximab from onset of GVHD, d (range) | 27 (4-59) |
| Median time from methylprednisolone to infliximab, d (range) | 25 (1-59) |
Characteristic . | No. (%)* . |
|---|---|
| Median age, y (range) | 47 (19-64) |
| Sex | |
| Male | 14 (67) |
| Female | 7 (33) |
| Stem cell source | |
| PBSC | 11 (52) |
| BM | 10 (48) |
| Donor source | |
| HLA-matched, related | 11 (52) |
| HLA-mismatched, related | 2 (10) |
| HLA-matched, unrelated | 8 (38) |
| Diagnosis | |
| MDS/AML | 6 (29) |
| CML/myelofibrosis | 4 (19) |
| Non-Hodgkin lymphoma | 6 (29) |
| ALL/CLL | 4 (19) |
| Myeloma | 1 (4) |
| Acute GVHD grade | |
| 1 | 3 (14) |
| 2 | 14 (67) |
| 3-4 | 4 (19) |
| Organ involvement, n (%) | |
| Skin | 9 (43) |
| GI tract | 12 (57) |
| Liver | 3 (14) |
| Median no. infliximab doses (range) | 4 (2-9) |
| Median time to infliximab from onset of GVHD, d (range) | 27 (4-59) |
| Median time from methylprednisolone to infliximab, d (range) | 25 (1-59) |
ALL indicates acute lymphocytic leukemia; AML, acute myelogenous leukemia; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem cells.
All data are numbers, with percentages shown in parentheses, unless otherwise indicated.